Nutex Health (NASDAQ:NUTX) Upgraded to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Nutex Health (NASDAQ:NUTX) from a hold rating to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

Other research analysts also recently issued reports about the stock. Weiss Ratings upgraded shares of Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, July 28th. B. Riley Financial began coverage on shares of Nutex Health in a research report on Friday, June 26th. They set a “buy” rating and a $290.00 target price for the company. Lake Street Capital restated a “buy” rating and set a $310.00 target price (up from $235.00) on shares of Nutex Health in a report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of Nutex Health from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $300.00.

Nutex Health Stock Up 0.3%

NASDAQ NUTX opened at $188.10 on Monday. The stock’s 50 day simple moving average is $168.99 and its 200 day simple moving average is $131.92. Nutex Health has a one year low of $77.21 and a one year high of $204.00. The firm has a market cap of $1.29 billion, a PE ratio of 7.39 and a beta of 0.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.00 and a quick ratio of 4.96.

Nutex Health (NASDAQ:NUTX) last announced its earnings results on Thursday, August 6th. The company reported $9.38 earnings per share for the quarter, beating analysts’ consensus estimates of $4.95 by $4.43. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%.The company had revenue of $210.75 million during the quarter, compared to analyst estimates of $215.03 million. As a group, sell-side analysts forecast that Nutex Health will post 30.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nutex Health

A number of large investors have recently modified their holdings of the business. Hussman Strategic Advisors Inc. acquired a new position in shares of Nutex Health during the 4th quarter worth approximately $3,457,000. Quantinno Capital Management LP bought a new position in shares of Nutex Health in the 1st quarter valued at about $843,000. First Trust Advisors LP raised its holdings in shares of Nutex Health by 60.0% in the 1st quarter. First Trust Advisors LP now owns 18,335 shares of the company’s stock valued at $1,743,000 after purchasing an additional 6,874 shares during the period. Empowered Funds LLC bought a new position in Nutex Health during the first quarter worth about $3,084,000. Finally, SG Americas Securities LLC increased its position in Nutex Health by 3,232.6% during the first quarter. SG Americas Securities LLC now owns 30,360 shares of the company’s stock worth $2,885,000 after buying an additional 29,449 shares during the last quarter. 5.32% of the stock is currently owned by institutional investors and hedge funds.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight?loss services and behavioral health support. By combining in?person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost?effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail?anchored centers, offering treatment for non?life?threatening injuries and illnesses, preventive screenings and basic primary care.